Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
Adriana Feder, Sara Costi, Sarah Rutter, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 2, pp. 193-202
Closed Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei Yan, Lijia Chang, Kenji Hashimoto
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 559-573
Open Access | Times Cited: 180
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 4, pp. 557-635
Closed Access | Times Cited: 94
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D. Henter, et al.
Discover Mental Health (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 83
Pharmacotherapy for post traumatic stress disorder (PTSD)
Taryn Williams, Nicole Phillips, Dan J. Stein, et al.
Cochrane library (2022) Vol. 2022, Iss. 3
Open Access | Times Cited: 76
The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Jichun Zhang, Wei Yao, Kenji Hashimoto
Neuropharmacology (2022) Vol. 218, pp. 109219-109219
Open Access | Times Cited: 69
To Predict, Prevent, and Manage Post-Traumatic Stress Disorder (PTSD): A Review of Pathophysiology, Treatment, and Biomarkers
Ghazi I. Al Jowf, Ziyad T. Ahmed, Rick A. Reijnders, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5238-5238
Open Access | Times Cited: 51
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Depression and Anxiety Disorders
Oğuz Karamustafalıoğlu, Hüseyin Yumrukçal
(2025), pp. 335-476
Closed Access | Times Cited: 7
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
Samuel Kohtala
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 323-345
Open Access | Times Cited: 92
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial
Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 8, pp. 1574-1581
Open Access | Times Cited: 61
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Rebecca B. Price, Nicholas Kissel, Andrew Baumeister, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 12, pp. 5096-5112
Open Access | Times Cited: 52
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies
Andrew H. Miller, Charles L. Raison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 68-75
Closed Access | Times Cited: 45
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Nicolas Singewald, Simone B. Sartori, Andreas Reif, et al.
Neuropharmacology (2023) Vol. 226, pp. 109418-109418
Open Access | Times Cited: 37
Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review
Bess M. Kew, Richard Porter, Katie M. Douglas, et al.
BJPsych Open (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 34
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Anya Ragnhildstveit, Jeremy Roscoe, Lisa C. Bass, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 29
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
Or Duek, Nachshon Korem, Yutong Li, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 11, pp. 1648-1658
Open Access | Times Cited: 23
The diverse effects of ketamine, jack-of-all-trades: a narrative review
Nicholas David Richards, Simon Howell, Michael Bellamy, et al.
British Journal of Anaesthesia (2025)
Closed Access | Times Cited: 1
A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice
Li Ma, Long Wang, Lijia Chang, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Jennifer Mitchell, B. Anderson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 96-103
Open Access | Times Cited: 21
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Abigail E. Calder, Seline Mock, Nicole Friedli, et al.
European Neuropsychopharmacology (2023) Vol. 75, pp. 1-14
Open Access | Times Cited: 19
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Sarah K. Fineberg, Esther Y. Choi, Rosa Shapiro-Thompson, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 7, pp. 991-999
Closed Access | Times Cited: 18
The Gut-Brain Axis and the Microbiome in Anxiety Disorders, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder
Marnie MacKay, Bohan H. Yang, Serdar Dursun, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 5, pp. 866-883
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top